# Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae

> **NCT00540072** · PHASE3 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)**

## Conditions studied

- Pneumonia, Bacterial

## Interventions

- **DRUG:** daptomycin

## Key facts

- **NCT ID:** NCT00540072
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07-30
- **Primary completion:** 2002-02-27
- **Final completion:** 2002-02-27
- **Target enrollment:** — (—)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540072, "Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00540072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*